Research location
Brindisi
BR, Italy
Advertisement
Research activity in Brindisi
BR, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 17 trials and 17 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Brindisi
17 linked trials · page 1 of 1stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective DatabaseNCT07397585 · 2025-02-25 · 1 site observation
RECRUITING
PREgnancy and FERtility RegistryNCT02895165 · 2012-11-01 · 1 site observation
RECRUITING
BRING-UP 3 Heart FailureNCT06279988 · 2023-09-15 · 1 site observation
UNKNOWN
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)NCT05156281 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantNCT03439046 · 2018-02-02 · 1 site observation
TERMINATED
BLITZ Heart FailureNCT03661060 · 2017-03-08 · 1 site observation
COMPLETED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabNCT02926196 · 2016-06-17 · 1 site observation
COMPLETED
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerNCT02246621 · 2014-11-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsNCT02511639 · 2014-07-30 · 1 site observation
COMPLETED
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast CancerNCT02918084 · 2013-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA TrialNCT02176369 · 2013-02-01 · 1 site observation
COMPLETED
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiNCT01633060 · 2012-10-03 · 1 site observation
TERMINATED
Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung CancerNCT01303926 · 2010-01-01 · 1 site observation
UNKNOWN
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleNCT00863655 · 2009-06-03 · 1 site observation
COMPLETED
Quetiapine Extended Release Depression SymptomsNCT00640562 · 2008-02-01 · 1 site observation
COMPLETED
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.NCT00412022 · 2004-03-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.